Summary
A bioRxiv preprint reports that parvalbumin interneurons and dentate-gyrus changes shape seizure susceptibility in Angelman syndrome model mice. The findings point to altered inhibitory control and homeostatic plasticity as possible drivers of epileptogenesis.
A bioRxiv preprint reports that specific inhibitory neurons and changes in the dentate gyrus help shape seizure susceptibility in mice modelling Angelman syndrome. The study, posted on September 19, 2026, found that loss of the maternal Ube3a allele in the model was associated with enhanced epileptogenesis—the process by which neural circuits become increasingly prone to seizures.
The work identifies parvalbumin-expressing interneurons as an important circuit component and describes a two-part failure of the brain's normal response to repeated seizure-provoking stimulation. The evidence is preclinical: it comes from genetically modified mice and is presented as a bioRxiv preprint.
Inhibitory neurons were central to the seizure phenotype
The researchers focused on parvalbumin-positive, or PV+, interneurons. These cells are a specialised class of inhibitory neuron that uses GABA signalling to restrain the activity and timing of nearby excitatory neurons. In healthy circuits, this inhibition helps prevent excessive synchronised activity.
In the Angelman syndrome model, selectively deleting the maternal Ube3a allele in PV+ interneurons reproduced the model's enhanced epileptogenesis. Conversely, restoring UBE3A broadly in GABAergic neurons— the wider group of neurons that use GABA as their main inhibitory transmitter—made the mice more resistant to seizures after kindling.
Kindling is an experimental method in which repeated stimulation gradually increases seizure susceptibility. It is used to study how a circuit can move from a relatively seizure-resistant state to a seizure-prone one. The genetic results place inhibitory neurons, rather than only excitatory cells, near the centre of that transition in this model.
A two-hit failure in the dentate gyrus
The study also highlighted the dentate gyrus, a hippocampal region that helps regulate how activity enters larger hippocampal circuits. Its principal neurons, called dentate granule cells, are excitatory and are normally controlled by inhibitory inputs.
In the Angelman syndrome model mice, kindling failed to recruit compensatory inhibition onto dentate granule cells. At the same time, the granule cells developed maladaptive intrinsic hyperexcitability, meaning that their own electrical properties made them more likely to fire. The authors describe these as a “two-hit” electrophysiologic process: inhibitory control did not strengthen as needed, while the excitatory cells themselves became more responsive.
This is an example of disrupted homeostatic plasticity. Neural circuits can normally adjust their properties to keep activity within a functional range. In the model, the seizure-inducing stimulation instead produced changes that favoured continued hyperexcitability.
The researchers further found that pathological remodelling of the extracellular matrix in the dentate gyrus tracked with seizure susceptibility after kindling. The extracellular matrix is the network of proteins and other molecules surrounding cells; changes in it can alter how neurons and synapses interact. In this study, the dentate-gyrus remodelling was associated with the post-kindling seizure phenotype and helped identify the region as especially relevant to enhanced epileptogenesis.
What the findings add
Angelman syndrome is linked to disrupted UBE3A function, and seizures are an important neurological feature of the condition. The new findings connect that genetic disruption to a more specific circuit mechanism: impaired PV+ interneuron function, inadequate compensatory inhibition and increased intrinsic excitability in dentate granule cells.
The results suggest that future treatment research could examine circuit-level approaches aimed at restoring inhibitory balance or correcting abnormal homeostatic responses. They do not constitute a treatment for Angelman syndrome or epilepsy. Because the evidence comes from a mouse model and a preprint, its relevance to people with Angelman syndrome and its potential therapeutic application require further study.